364 patients continued in a 28-week open label extension during which they received teneligliptin 20 mg OD In initial 24 weeks, addition of teneligliptin reduced HbA1c by 0.63%. this response was maintained in 28 weeks extension with 20 mg teneligliptin. Treatment was well tolerated and the overall incidence of hypoglycemia during 52 weeks was 2.3% only.
The study concluded that Teneligliptin co-administered with metformin produced significant reductions in HbA1c in patients with T2DM without increasing the risk of hypoglycemia.
Link for Abstract/Full text: http://dx.doi.org/10.1080/14656566.2016.1190334
In Indian study, teneligliptin reduced HbA1c by 1.28% (Baseline HbA1c: 10.2%)
Link for Abstract/Full text: http://am.aace.com/sites/all/files/Late-Breaking-2016.pdf
A DPP-4 inhibitor for the treatment of type 2 diabetes
Link for Abstract/Full text: http://www.ncbi.nlm.nih.gov/pubmed/23671395